Biomet says scope of antitrust investigation narrowed

By Elaine Rigoli

Tampa, Fla., July 28 - Biomet said Friday that the scope of the antitrust investigation, previously disclosed June 26, has been narrowed to a specific geographic region and specific product lines.

The company said it believes the investigation was prompted by an unsolicited e-mail sent by a representative of one of Biomet's competitors that proposed a common pricing strategy in connection with a particular hospital.

This e-mail was received by an independent sales representative of an independent Biomet distributor, but it was never transmitted to Biomet, the company said in a news release.

Biomet said it did not take any action in response to the e-mail.

Based in Warsaw, Ind., Biomet markets products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.